Acadia buys clinical-stage biotechnology company CerSci Therapeutics
Acadia Pharmaceuticals has added novel pain programme to its portfolio with the acquisition of clinical-stage biotechnology company CerSci Therapeutics.
Acadia Pharmaceuticals has added novel pain programme to its portfolio with the acquisition of clinical-stage biotechnology company CerSci Therapeutics.
Bristol Myers Squibb (BMS) has signed an agreement to acquire clinical-stage protein engineering company Forbius for an undisclosed sum.
AbCellera announced the acquisition of the OrthoMab bispecific platform from Dualogics, LLC. (Dualogics).
Johnson & Johnson (J&J) has agreed to acquire Momenta Pharmaceuticals, a Massachusetts-based biotech company focused on immune-mediated diseases, in an all-cash deal worth around $6.5bn.
CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch today to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19.
Bristol Myers Squibb (BMS) has agreed to acquire the global exclusive licensing rights to interleukin-12 (IL-12), an investigational immunotherapy programme from Dragonfly Therapeutics, in a deal worth more than $475m.
Biopharmaceutical company Gilead Sciences has expanded its strategic oncology collaboration with biotechnology company Tango Therapeutics.
This edition of the health sciences Journal is about hope and optimism, and how we must rethink our ways of working.
French drugmaker Sanofi has agreed to acquire late-stage biopharmaceutical company Principia Biopharma for an aggregate equity value of around $3.68bn.
UNION therapeutics announced the completion of an agreement with TFF Pharmaceuticals (TFF) to acquire an option to obtain a worldwide exclusive license for the use of their Thin Film Freezing technology in combination with niclosamide to focus on treatments for COVID-19.